Answers are grounded in this paper and cite their sources.
The prescribed doses for many drugs are based on population norms or vary between physicians. For example, very low birth weight (VLBW) infants (weighing less than 1500 grams at birth) experience slower postnatal growth than in utero and receive glucose infusions to mitigate nutritional disruption. Effective treatment dosing is critical to ensure adequate neonatal weight gain while minimizing the risk of hyperglycemia. A single uniform dose is impractical due to the substantial heterogeneity in glucose metabolism among infants. Furthermore, little is known about each infant’s glucose metabolism, which complicates the selection of the optimal dose value. We employ a flexible longitudinal mixed model to determine dynamic, patient-specific optimal doses for new infants. Empirical Bayes predictions of random effects are incorporated to capture individual dosage sensitivities that adapt as new data becomes available. To be viable in high-risk clinical environments, providing estimates of predictive uncertainty is crucial for supporting informed clinical decision-making that balances patient safety with treatment efficacy. We propose using the implicit value delta method to quantify the uncertainty of the predicted optimal doses. We validate the properties of our model through simulation studies and an analysis of VLBW infants in a neonatal intensive care unit (NICU) for the first 7 days of life, which demonstrates some key differences in optimal and prescribed dosing strategies.
No takes yet. Share an insight, caveat, or question.
Nishat et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: